Peter E Czabotar

26PUBLICATIONS
138CO-AUTHORS
Biologically active moleculesMolecular targetsMedical infection agents (incl. prions)Cheminformatics and quantitative structure-activity relationshipsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 05, 2025
Computational design of potent and selective binders of BAK and BAX.

Stephanie Berger, Erinna F Lee, Tiffany J Harris

|Apr 09, 2025
The BCL-2 protein family: from discovery to drug development.

Carlo M Croce, David Vaux, Andreas Strasser

|Apr 03, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

Stefanie M Bader, Dale J Calleja, Shane M Devine

|Mar 05, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Kaiming Li, Yu Q Yap, Donia M Moujalled

|Mar 04, 2025
Structure-activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors.

Anthony N Hodder, Brad E Sleebs, Greg Adams

|Apr 06, 2024
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells.

Hema Preethi Subas Satish, Sweta Iyer, Melissa X Shi

Pageof 5

Frequent Collaborators

10 joint publications

James M Murphy

9 joint publications

Richard W Birkinshaw

7 joint publications

Guillaume Lessene

6 joint publications

Jarrod J Sandow